Oscar Health (OSCR)
(Delayed Data from NYSE)
$16.59 USD
+0.72 (4.54%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $16.60 +0.01 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Income Statements
Fiscal Year end for Oscar Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5,863 | 3,964 | 1,839 | 463 | 488 |
Cost Of Goods | 4,642 | 3,281 | 1,624 | 309 | 408 |
Gross Profit | 1,221 | 683 | 215 | 153 | 80 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,456 | 1,273 | 759 | 556 | 339 |
Income After Depreciation & Amortization | -236 | -590 | -544 | -402 | -259 |
Non-Operating Income | -7 | 2 | -21 | 0 | 0 |
Interest Expense | 25 | 23 | 5 | 4 | 0 |
Pretax Income | -267 | -610 | -571 | -406 | -259 |
Income Taxes | 3 | -1 | 1 | 1 | 2 |
Minority Interest | 0 | -3 | 1 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -271 | -610 | -571 | -407 | -261 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -271 | -606 | -573 | -407 | -261 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -234 | -571 | -522 | -388 | -259 |
Depreciation & Amortization (Cash Flow) | 2 | 18 | 23 | 14 | 0 |
Income After Depreciation & Amortization | -236 | -590 | -544 | -402 | -259 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 221.66 | 212.48 | 178.97 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.22 | -2.85 | -3.20 | NA | NA |
Diluted Net EPS (GAAP) | -1.22 | -2.85 | -3.20 | -4.72 | NA |
Fiscal Year end for Oscar Health, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 2,142.31 | 1,431.66 | 1,439.99 | 1,521.54 | 1,469.69 |
Cost Of Goods | 1,554.77 | 1,205.24 | 1,163.19 | 1,182.00 | 1,091.59 |
Gross Profit | 587.53 | 226.42 | 276.80 | 339.54 | 378.09 |
SG&A, R&D, and Dept/Amort Expenses | 401.97 | 371.90 | 335.04 | 346.07 | 403.46 |
Income After SG&A, R&D, and Dept/Amort Expenses | 185.56 | -145.48 | -58.24 | -6.53 | -25.37 |
Non-Operating Income | -1.18 | 1.05 | -0.41 | -1.61 | -6.11 |
Interest Expense | 5.90 | 6.22 | 6.13 | 6.12 | 6.14 |
Pretax Income | 178.48 | -150.64 | -64.79 | -14.26 | -37.61 |
Income Taxes | 1.00 | -0.81 | 0.92 | 1.16 | 2.02 |
Minority Interest | 0.11 | 0.19 | -0.31 | 0.10 | 0.14 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 177.48 | -149.84 | -65.70 | -15.43 | -39.63 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 177.37 | -150.03 | -65.40 | -15.53 | -39.77 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 293.80 | 227.08 | 223.10 | 219.40 | 216.91 |
Diluted EPS Before Non-Recurring Items | 0.62 | -0.66 | -0.29 | -0.07 | -0.18 |
Diluted Net EPS (GAAP) | 0.62 | -0.68 | -0.29 | -0.07 | -0.18 |